Exscientia PLC is a United Kingdom-based artificial intelligence (AI)-driven precision medicine company. It is focused on discovering, designing, and developing the possible drugs. It has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Its internal pipeline is focused on leveraging its precision medicine platform in oncology, while its partnered pipeline broadens its approach to other therapeutic areas. Its patient-first AI platform includes Patient-first AI, Precision Target, Precision Design, Precision Experiment, and Precision Medicine. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Companyâs advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI-design.
More about the company